Status:
WITHDRAWN
Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours
Lead Sponsor:
AstraZeneca
Conditions:
Cancer
Advanced Solid Tumours
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
To investigate the safety and tolerability of AZD8055 intermittent dosing schedules when given orally to patients with advanced solid malignancies and lymphomas. Two intermittent dosing schedules will...
Eligibility Criteria
Inclusion
- Histological or cytological confirmation of an advanced solid malignant tumour or lymphoma which is refactory to standard therapies or for which no standard therapy exists, patients with measurable or non-measurable disease (according to RECIST criteria)
- WHO performance status 0-2
- Evidence of post-menopausal status or negative urine/serum pregnancy test for pre-menopausal female patients
Exclusion
- Patients with severe laboratory abnormalities for haematology, liver or renal function. Also treatment with any haemopoietic growth factors are not allowed within two weeks from first dose of study drug.
- Any investigational agents or study drugs from a previous clinical study within 30 days, any other chemotherapy, immunotherapy or anticancer agents within 3 weeks of the first dose of study treatment
- Patients with severe cardiac condition of ischemia, impaired ventricular function and arrhythmias, evidence of severe or uncontrolled systemic or current unstable or uncompensated respiratory or cardiac conditions
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT01194193
Last Update
May 16 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.